Abstract
Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. It was first identified in bacterial cell wall peptidoglycan as an active component in Freunds complete adjuvant. In the cell, MDP is detected by NOD2, a cytoplasmic receptor belonging to the human innate immune system. NOD2 mutations are frequently observed in patients with Crohns disease, an autoimmune disorder, suggesting the significance of the MDP-NOD2 pathway in activating immunity. For this reason, structural modifications of MDP and its derivatives have been extensively studied in an attempt to increase adjuvant activity and boost the immune response effectively for clinical use in the treatment of cancer and other diseases. This review summarizes the synthetic chemistry of MDP and its derivatives and discusses their pharmacological action and stereoselective synthesis.
Keywords: Adjuvant, derivatives, immunological disorders, cancer therapy, anti-cancer, anti-inflammatory, MDP, MDP synthesis, medicinal application, peptidoglycan
Current Bioactive Compounds
Title: Muramyl Dipeptide and its Derivatives: Peptide Adjuvant in Immunological Disorders and Cancer Therapy
Volume: 7 Issue: 3
Author(s): Chikako Ogawa, Yuen-Joyce Liu and Koichi S. Kobayashi
Affiliation:
Keywords: Adjuvant, derivatives, immunological disorders, cancer therapy, anti-cancer, anti-inflammatory, MDP, MDP synthesis, medicinal application, peptidoglycan
Abstract: Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. It was first identified in bacterial cell wall peptidoglycan as an active component in Freunds complete adjuvant. In the cell, MDP is detected by NOD2, a cytoplasmic receptor belonging to the human innate immune system. NOD2 mutations are frequently observed in patients with Crohns disease, an autoimmune disorder, suggesting the significance of the MDP-NOD2 pathway in activating immunity. For this reason, structural modifications of MDP and its derivatives have been extensively studied in an attempt to increase adjuvant activity and boost the immune response effectively for clinical use in the treatment of cancer and other diseases. This review summarizes the synthetic chemistry of MDP and its derivatives and discusses their pharmacological action and stereoselective synthesis.
Export Options
About this article
Cite this article as:
Ogawa Chikako, Liu Yuen-Joyce and S. Kobayashi Koichi, Muramyl Dipeptide and its Derivatives: Peptide Adjuvant in Immunological Disorders and Cancer Therapy, Current Bioactive Compounds 2011; 7 (3) . https://dx.doi.org/10.2174/157340711796817913
DOI https://dx.doi.org/10.2174/157340711796817913 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Tumor-Associated Antigens to the MHC Class I Presentation Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets Vascular Mimicry: Concepts and Implications for Anti-Angiogenic Therapy
Current Angiogenesis (Discontinued) Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?
Reviews on Recent Clinical Trials Regulation of T cell Apoptosis during the Immune Response
Current Molecular Medicine Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry An Unexpected Diagnosis of Liver Metastases on a Bone Scan
Current Radiopharmaceuticals Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Integrase Interactor 1 in Health and Disease
Current Protein & Peptide Science PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Vascular Targeting: A New Antitumor Activity
Drug Design Reviews - Online (Discontinued) Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets Synthesis of Novel Test Compounds for Antiviral Chemotherapy of Severe Acute Respiratory Syndrome (SARS)
Current Medicinal Chemistry State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry Gene Therapy in Plastic and Reconstructive Surgery
Current Gene Therapy Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways
Current Neuropharmacology